Small Fiber Neuropathy: Symptoms, Diagnosis, and Treatment

Small fiber neuropathy is a form of nerve damage that affects the thinnest, unmyelinated nerve fibers — C fibers and A-delta fibers. It causes burning pain, hypersensitivity, and autonomic dysfunction (dry skin, abnormal sweating, temperature dysregulation), but standard nerve conduction studies come back normal. This is why many patients are told their tests are "fine" while their symptoms are real and progressive. Diagnosis requires skin biopsy or quantitative sensory testing.

This guide draws on peer-reviewed research from three specialists whose work has shaped how small fiber neuropathy is understood and treated today: Thomas Brannagan, MD, Professor of Neurology at Columbia University, whose characterization of the non-length-dependent ganglionopathy form of SFN [2] and extensive experience with IVIG in neurological disease [1] have directly informed clinical practice; Eva Feldman, MD, PhD, whose two-step diagnostic framework for diabetic neuropathy [3] and mechanistic research on C-fiber bioenergetics [4] illuminate why small fibers are uniquely vulnerable to metabolic injury; and Michael Rowbotham, MD, of UCSF, whose NeuPSIG assessment guidelines [6] and contributions to the IASP classification of chronic neuropathic pain [5] provide the diagnostic and nomenclature framework clinicians use today.

What makes small fibers different

The peripheral nervous system contains nerve fibers of different sizes, and size determines function. Large, heavily myelinated A-beta fibers carry signals for vibration, joint position sense, and touch — the signals that standard nerve conduction studies (NCS) and electromyography (EMG) are designed to detect. Small fibers operate differently. C fibers are unmyelinated and carry slow pain signals, heat sensation, and autonomic traffic — regulating sweat glands, blood vessel tone, and skin blood flow. A-delta fibers are lightly myelinated and carry fast pain and cold temperature signals.

Because NCS and EMG rely on measuring the conduction velocity of large myelinated fibers, they are entirely blind to small-fiber pathology. A patient with severe small fiber neuropathy can have a completely normal EMG. This is not a false negative — it is a fundamental limitation of the test. Feldman and colleagues demonstrated how a two-step clinical and electrophysiological approach captures large-fiber disease well [3], but that framework also defines the gap: small-fiber dysfunction requires separate, dedicated testing. Feldman's 2017 mechanistic review in Neuron traced how impaired mitochondrial bioenergetics in C fibers drives the earliest damage in metabolic neuropathy, explaining why painful, small-fiber-predominant neuropathy often precedes any measurable large-fiber loss [4].

Symptoms of small fiber neuropathy

The hallmark symptom is burning pain in the feet — described by patients as "walking on hot coals," "standing in fire," or having feet that feel like they are being held against a heating element. The pain is often worst at night, when the warmth of bedsheets becomes intolerable.

Two related phenomena amplify the burden:

• Hyperalgesia: an exaggerated pain response to stimuli that should be mildly painful, such as a slight pinch or temperature that is only moderately warm
• Allodynia: pain triggered by stimuli that should not hurt at all — the weight of a bedsheet on the feet, the texture of carpet underfoot, a light breeze across the skin

Autonomic symptoms accompany the sensory pain in many patients: the feet may be abnormally dry (reduced sweat gland function) or paradoxically sweaty; heat intolerance can be severe; dizziness on standing (orthostatic hypotension from impaired vascular regulation) is common; and some patients notice temperature dysregulation of the skin. These autonomic features occur because the same small C fibers that carry pain also innervate sweat glands and blood vessels.

Brannagan and colleagues described these symptoms in the context of both the typical length-dependent form and the less common non-length-dependent ganglionopathy form, demonstrating that autonomic involvement is a consistent feature across both patterns [2].

Length-dependent vs. non-length-dependent forms

Most small fiber neuropathy follows a length-dependent pattern: it begins in the toes and the soles of the feet, then slowly ascends toward the ankles and calves as the longest nerve fibers fail first. This pattern is strongly associated with metabolic causes — diabetes, prediabetes, impaired glucose tolerance, and chronic alcohol use.

The non-length-dependent form, sometimes called small fiber ganglionopathy, presents differently. Symptoms appear in a patchy or widespread distribution that may involve the face, the scalp, the torso, or the arms from the outset — not a feet-first ascent. This pattern points toward damage at the level of the dorsal root ganglia rather than the nerve axon itself, and it suggests an immune-mediated or metabolic cause that is attacking the cell body rather than the distal fiber.

Brannagan and colleagues characterized a cohort of patients with this non-length-dependent form in their 2007 Journal of Neurology, Neurosurgery & Psychiatry paper [2]. A cause — immune, metabolic, or hereditary — was identified in approximately half of patients; the remainder had idiopathic ganglionopathy. Patients in this group were more likely to be refractory to standard symptomatic treatments, underscoring the importance of searching for a treatable underlying cause.

Causes and associations

The most common identifiable cause of small fiber neuropathy is impaired glucose metabolism. Prediabetes and impaired glucose tolerance — stages that precede a formal diabetes diagnosis — can damage small fibers before large fibers are affected and before a routine glucose test would flag a problem. A fasting glucose and hemoglobin A1c are therefore essential in any workup.

Other recognized causes include:

• Immune-mediated conditions: Sjogren's syndrome, systemic lupus erythematosus, and sarcoidosis are among the most frequently associated. An immune cause is particularly worth pursuing in patients with the non-length-dependent pattern.
• Hereditary sodium channelopathies: Gain-of-function mutations in the SCN9A gene (encoding the Nav1.7 sodium channel) cause a form of SFN that is painful, early in onset, and — importantly — specifically responsive to sodium channel blockers such as carbamazepine. Genetic testing is appropriate in younger patients or those with a family history of similar symptoms.
• Idiopathic: Approximately 40 percent of patients have no identifiable cause found after a complete evaluation. Idiopathic SFN tends to be more stable over time than secondary forms, but it remains symptomatic and deserves treatment.
• Medications: Statins are occasionally implicated in small-fiber pathology, though the association is less firmly established than for large-fiber neuropathy from chemotherapy.

How it is diagnosed

The diagnostic starting point for small fiber neuropathy is a normal EMG and nerve conduction study — confirming that large fibers are intact and that the symptoms arise from the small-fiber compartment. This is not a failure of the workup; it is a diagnostic feature.

Definitive confirmation relies on two specialized tests:

Skin punch biopsy is the most widely accepted test. A small 3-millimeter punch biopsy is taken from the distal leg (typically 10 cm above the lateral malleolus) and often from the thigh as well. The specimen is processed with immunofluorescence staining to visualize intraepidermal nerve fibers — the tiny terminal branches of C fibers that extend through the epidermis. An abnormally low intraepidermal nerve fiber density, compared against age- and sex-matched reference values, confirms small fiber neuropathy. The test is quantitative, reproducible, and can be repeated to track progression or treatment response.

Quantitative sensory testing (QST) measures the thresholds at which a patient detects warmth, cool, heat pain, and cold pain. Elevated thresholds for these modalities — meaning the patient needs a more extreme stimulus to feel anything — point to small-fiber dysfunction. Rowbotham and colleagues developed and validated the assessment approaches for these thresholds in the NeuPSIG guidelines [6], which also established the grading framework (possible, probable, definite neuropathic pain) that clinicians now use to structure diagnosis.

The IASP chronic pain classification for ICD-11, to which Rowbotham contributed, formally recognizes small fiber neuropathy as a distinct entity within chronic peripheral neuropathic pain — giving clinicians a precise diagnostic code and patients a legitimate clinical category [5].

Treatment: addressing the cause first

Before reaching for symptomatic medications, the first priority is identifying and treating any reversible underlying cause.

• Diabetes and prediabetes: Stabilizing blood glucose — through lifestyle modification, metformin, or other agents — is the most evidence-based intervention for slowing small-fiber progression in metabolic neuropathy. The earlier glucose is controlled, the better the outcome.
• Immune-mediated SFN: Patients with Sjogren's syndrome, sarcoidosis, or other immune causes may respond to immunosuppressive therapy. Intravenous immunoglobulin (IVIG) has been used with benefit in immune-mediated SFN. Brannagan has published extensively on IVIG for neurological diseases [1] and brings direct clinical experience to this approach at Columbia.
• Nav1.7 channelopathy: Carbamazepine and other sodium channel blockers are specifically helpful in SCN9A-related SFN, given the mechanism — a hyperactive sodium channel that generates ectopic firing. This is one of the few cases in neuropathic pain where a mechanism-targeted therapy exists.

Symptomatic pain management

For patients whose cause cannot be fully treated, or while disease-modifying therapy is taking effect, several agents reduce pain:

• Gabapentin and pregabalin (alpha-2-delta calcium channel modulators) are first-line agents for neuropathic pain. They reduce ectopic firing in sensitized pain neurons and are supported by extensive trial data.
• Duloxetine (an SNRI) is also first-line and is particularly useful when depression or fatigue accompanies the neuropathy.
• Low-dose tricyclic antidepressants (amitriptyline, nortriptyline) taken at night provide both analgesia and sleep benefit — useful given that SFN pain is often worst at night.
• Topical agents — 5% lidocaine patches or high-concentration capsaicin (8%) applied to affected areas — work locally without systemic exposure, making them attractive for patients who cannot tolerate oral medications.
• IVIG has demonstrated benefit in immune-mediated SFN and is considered for patients with confirmed immunological causes who have not responded to first-line oral agents.

Rowbotham and colleagues outlined the pharmacotherapy evidence base in the NeuPSIG assessment guidelines [6], providing the graded framework that clinicians use to select and sequence these agents.

What to expect over time

The trajectory of small fiber neuropathy depends heavily on cause. Idiopathic SFN tends to be relatively stable — symptoms may plateau and remain manageable for years without significant progression. Immune-mediated forms often improve substantially with appropriate immunotherapy, sometimes dramatically so in IVIG-responsive cases. Diabetes-related SFN is progressive if glucose is not controlled, but stabilization and partial improvement are achievable with rigorous metabolic management. Nav1.7 channelopathy is chronic but often responds well to sodium channel blockade, allowing meaningful functional improvement.

Questions to ask your neurologist

• My EMG was normal — does that rule out neuropathy, or should I have a skin biopsy or quantitative sensory testing?
• What is the most likely cause of my small fiber neuropathy, and are there treatable conditions — like prediabetes or an immune disease — we should test for?
• Is my pattern length-dependent (starting in the feet) or non-length-dependent, and what does that mean for the likely cause?
• If an immune cause is found, am I a candidate for IVIG or other immunotherapy?
• What is the best medication for my pain, and how long should I try it before deciding whether it is working?

The bottom line

Small fiber neuropathy is a real, diagnosable, and often treatable condition — not an unexplained complaint or a symptom without a cause. The fact that a normal EMG does not rule it out is one of the most important things a patient with burning pain and autonomic symptoms can understand. Skin biopsy confirms the diagnosis, a thorough metabolic and immune workup frequently identifies a treatable cause, and multiple effective therapies exist for both the underlying disease and the pain itself. The right starting point is a neurologist who knows to look beyond the EMG.